

R H I N O M E D


BTNX AND RHINOMED FINALISE SUPPLY AGREEMENT FOR RHINOSWAB

- 24 month Rhinoswab and Rhinoswab Junior supply agreement with BTNX Inc. – one of Canada’s largest rapid antigen test (RAT) kit manufacturers.
- Agreement on an exclusive basis for the Canadian market and non-exclusive in other markets.
- Rhinomed will supply a minimum of 22.5 million swabs over the course of the term.

7th April 2022: Melbourne, Australia.

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, is pleased to confirm that it has entered into a supply agreement with BTNX Inc. – one of Canada’s largest manufacturers of rapid antigen test kits.

The supply agreement is for a period of 24 months and covers the supply of Rhinoswab and Rhinoswab Junior for inclusion in BTNX’s range of Covid-19 Rapid Response antigen test kits. This includes supply of Rhinoswab Junior for inclusion in the new *Rapid Response COVID-19 Antigen Rapid Test Cassette - Junior Home Test Featuring Rhinoswab Junior* – one of the world’s first rapid antigen test kits designed for children.



BTNX is a world leader in rapid, point of care diagnostics across a range of markets. BTNX is the largest supplier of rapid antigen test kits to the Canadian government where it has supplied over 315 million rapid antigen tests to date.

BTNX and Rhinomed can advise that the supply agreement contains standard terms for an agreement of this nature and provides for a minimum binding commitment of 22.5 million swabs over a 24 month period. The agreement is exclusive in the Canadian market and non-exclusive in all other markets. BTNX has informed Rhinomed orders will commence in July 2022.

R H I N O M E D

Pricing remains commercial in confidence however investors should note that the revenue associated with this arrangement has the potential to represent approximately 465% to 475% of reviewed H1FY22 revenues of \$3.75m.

Michael Johnson CEO of Rhinomed said, *"The completion of this supply agreement with BTNX is an indicator of the strong market feedback BTNX has received and the impending completion of the Canadian regulatory approval process. The BTNX Rapid Response with Rhinoswab Junior has the potential to transform the way children in Canada are tested. We look forward to a long and successful partnership with BTNX."*

BTNX CEO Iqbal Sunderani said *"In the completion of this agreement with Rhinomed, we are pleased to have progressed one step closer to our shared goal of improving the testing experience for children and parents alike. We look forward to our continued collaboration with Rhinomed as we bring this exciting new product to our key markets."*

This report has been authorised for release to the market by the Board. This announcement discloses all material details as required under section 4.1 of ASX Guidance Note 8 in respect of the Supply Agreement.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.